Athira Pharma, Inc.
ATHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.04 | -0.02 | -0.06 |
| FCF Yield | -430.32% | -109.38% | -61.54% | -9.29% |
| EV / EBITDA | 0.26 | -0.03 | -0.29 | -6.85 |
| Quality | ||||
| ROIC | -219.08% | -95.21% | -43.88% | -19.82% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.00 | 0.86 | 0.76 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 3.81% | -37.29% | -64.78% | -69.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.49 | 0.71 | 1.07 | 2.00 |
| Interest Coverage | 0.00 | 0.00 | -4.28 | -21,340.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -432.06 |